Annals of neurology Journal

•  
• Overview
•  
• Identity
•  
• View All
•  

Overview

publication venue for

• Lower Locus Coeruleus Integrity Signals Elevated Entorhinal Tau and Clinical Progression in Asymptomatic Older Individuals..  96:650-661. 2024
• Unexpected Low Rate of Amyloid-β Pathology in Multiple Sclerosis Patients..  96:453-459. 2024
• Plasma pTau181 Reveals a Pathological Signature that Predicts Cognitive Outcomes in Lewy Body Disease..  96:526-538. 2024
• Timing of Biomarker Changes in Sporadic Alzheimer's Disease in Estimated Years from Symptom Onset..  95:951-965. 2024
• Intensive Blood Pressure Treatment and Subclinical Brain Infarcts: A Secondary Analysis of SPRINT (Systolic Pressure Intervention Trial)..  95:866-875. 2024
• Early Detection of Amyloid-Related Changes in Memory among Cognitively Unimpaired Older Adults with Daily Digital Testing..  95:507-517. 2023
• Relationships of Cognitive Measures with Cerebrospinal Fluid but Not Imaging Biomarkers of Alzheimer Disease Vary between Black and White Individuals..  95:495-506. 2023
• Reply to "A Letter Concerning a Role for Blood-Brain Barrier Dysfunction in Delirium following Noncardiac Surgery in Older Adults"..  95:411-413. 2023
• Diagnostic Utility of Cerebrospinal Fluid Biomarkers in Patients with Rapidly Progressive Dementia..  95:299-313. 2023
• Combined Connectomics, MAPT Gene Expression, and Amyloid Deposition to Explain Regional Tau Deposition in Alzheimer Disease..  95:274-287. 2023
• Eligibility Rates among Racially and Ethnically Diverse US Participants in Phase 2 and Phase 3 Placebo-Controlled, Double-Blind, Randomized Trials of Lecanemab and Elenbecestat in Early Alzheimer Disease..  95:288-298. 2023
• Predicting Functional Dependency in Patients with Disorders of Consciousness: A TBI-Model Systems and TRACK-TBI Study..  94:1008-1023. 2023
• Association of Chronic Pain with Biomarkers of Neurodegeneration, Microglial Activation, and Inflammation in Cerebrospinal Fluid and Impaired Cognitive Function. 2023
• A Role for Blood-brain Barrier Dysfunction in Delirium following Non-Cardiac Surgery in Older Adults..  94:1024-1035. 2023
• Distinct Patterns of Hippocampal Pathology in Alzheimer's Disease with Transactive Response DNA-binding Protein 43..  94:1036-1047. 2023
• Reply to Suvorexant for Preventing Alzheimer's Disease..  94:414-415. 2023
• Frontotemporal Degeneration with Transactive Response DNA-Binding Protein Type C at the Anterior Temporal Lobe..  94:1-12. 2023
• Suvorexant Acutely Decreases Tau Phosphorylation and Aβ in the Human CNS..  94:27-40. 2023
• Biological Age Acceleration and Motoric Cognitive Risk Syndrome..  93:1187-1197. 2023
• Circadian Rest-Activity Rhythms, Delirium Risk, and Progression to Dementia..  93:1145-1157. 2023
• Illusory Responses across the Lewy Body Disease Spectrum..  93:702-714. 2023
• APOE2 Exacerbates TDP-43 Related Toxicity in the Absence of Alzheimer Pathology..  93:830-843. 2023
• Alzheimer's Disease Genetic Risk, Cognition, and Brain Aging in Midlife..  93:629-634. 2022
• Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease..  92:729-744. 2022
• Venous Collagenosis as Pathogenesis of White Matter Hyperintensity..  92:992-1000. 2022
• Tau Mediates Synergistic Influence of Vascular Risk and Aβ on Cognitive Decline..  92:745-755. 2022
• α-Synuclein Seed Amplification in CSF and Brain from Patients with Different Brain Distributions of Pathological α-Synuclein in the Context of Co-Pathology and Non-LBD Diagnoses..  92:650-662. 2022
• Progressive White Matter Injury in Preclinical Dutch Cerebral Amyloid Angiopathy..  92:358-363. 2022
• Menopause Status Moderates Sex Differences in Tau Burden: A Framingham PET Study..  92:11-22. 2022
• APOE Antibody Inhibits Aβ-Associated Tau Seeding and Spreading in a Mouse Model..  91:847-852. 2022
• Greater Diffusion Restriction in White Matter in Preclinical Alzheimer Disease..  91:864-877. 2022
• COVID-19 Vaccine Response in People with Multiple Sclerosis..  91:89-100. 2021
• Aducanumab: What about the Patient?.  90:334-335. 2021
• Human Brain Resilience: A Call to Action..  90:336-349. 2021
• Electroencephalographic Abnormalities are Common in COVID-19 and are Associated with Outcomes..  89:872-883. 2021
• Apolipoprotein E4 Reduction with Antisense Oligonucleotides Decreases Neurodegeneration in a Tauopathy Model..  89:952-966. 2021
• Socioeconomic Status Mediates Racial Differences Seen Using the AT(N) Framework..  89:254-265. 2020
• Genetic Risk of Alzheimer's Disease and Sleep Duration in Non-Demented Elders..  89:177-181. 2020
• Sex Mediates Relationships Between Regional Tau Pathology and Cognitive Decline..  88:921-932. 2020
• Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer's Disease..  88:183-194. 2020
• Genetically Elevated LDL Associates with Lower Risk of Intracerebral Hemorrhage..  88:56-66. 2020
• Sleep Deprivation Affects Tau Phosphorylation in Human Cerebrospinal Fluid..  87:700-709. 2020
• Association of Plasma Neurofilament Light with Postoperative Delirium..  88:984-994. 2020
• Amyloid imaging of dutch-type hereditary cerebral amyloid angiopathy carriers..  86:616-625. 2019
• The impact of amyloid-beta and tau on prospective cognitive decline in older individuals..  85:181-193. 2019
• Obstructive sleep apnea treatment, slow wave activity, and amyloid-β..  85:291-295. 2019
• Vascular Risk and β-Amyloid Are Synergistically Associated with Cortical Tau..  85:272-279. 2019
• Higher urate in LRRK2 mutation carriers resistant to Parkinson disease..  85:593-599. 2019
• Reply to "Mitochondrial DNA deletions discriminate affected from unaffected LRRK2 mutation carriers"..  86:326-327. 2019
• Prevalence of amyloid-β pathology in distinct variants of primary progressive aphasia..  84:729-740. 2018
• Atrophy and microglial distribution in primary progressive aphasia with transactive response DNA-binding protein-43 kDa..  83:1096-1104. 2018
• Reduced contrast sensitivity among older women is associated with increased risk of cognitive impairment..  83:730-738. 2018
• Reply to "Excess amyloid beta can be degraded in healthy humans"..  83:650-651. 2018
• Effect of sleep on overnight cerebrospinal fluid amyloid β kinetics..  83:197-204. 2018
• Neuroimaging biomarkers and impaired olfaction in cognitively normal individuals..  81:871-882. 2017
• Fluorodeoxyglucose metabolism associated with tau-amyloid interaction predicts memory decline..  81:583-596. 2017
• Reply..  81:322-323. 2017
• The melanoma-linked "redhead" MC1R influences dopaminergic neuron survival..  81:395-406. 2017
• Episodic memory of odors stratifies Alzheimer biomarkers in normal elderly..  80:846-857. 2016
• Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease..  80:379-87. 2016
• White matter integrity as a mediator in the relationship between dietary nutrients and cognition in the elderly..  79:1014-25. 2016
• White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network..  79:929-39. 2016
• Compound heterozygous FXN mutations and clinical outcome in friedreich ataxia..  79:485-95. 2016
• Is in vivo amyloid distribution asymmetric in primary progressive aphasia?.  79:496-501. 2016
• Obstructive sleep apnea decreases central nervous system-derived proteins in the cerebrospinal fluid..  80:154-9. 2016
• Tau positron emission tomographic imaging in aging and early Alzheimer disease..  79:110-9. 2015
• Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue..  78:787-800. 2015
• Olfactory identification deficits and increased mortality in the community..  78:401-11. 2015
• A pharmacogenetic study implicates SLC9a9 in multiple sclerosis disease activity..  78:115-27. 2015
• Traumatic brain injury in later life increases risk for Parkinson disease..  77:987-95. 2015
• A TREM1 variant alters the accumulation of Alzheimer-related amyloid pathology..  77:469-77. 2015
• Apolipoprotein E levels and Alzheimer risk..  77:204-5. 2015
• Mutual exacerbation of peroxisome proliferator-activated receptor γ coactivator 1α deregulation and α-synuclein oligomerization..  77:15-32. 2014
• Friedreich ataxia: new findings, new challenges..  76:487-8. 2014
• Reply: To PMID 24687915..  76:630-1. 2014
• Nonconvulsive seizures in subarachnoid hemorrhage link inflammation and outcome..  75:771-81. 2014
• Modulation of amyloid precursor protein expression reduces β-amyloid deposition in a mouse model..  75:684-99. 2014
• Mild to moderate Alzheimer dementia with insufficient neuropathological changes..  75:597-601. 2014
• Traumatic brain injury may increase risk of young onset dementia..  75:339-41. 2014
• Mendelian randomization of serum urate and parkinson disease progression..  76:862-8. 2014
• Dual effects of β-synuclein on the pathogenesis of Parkinson disease..  74:-. 2013
• Nonconvulsive seizures after subarachnoid hemorrhage: Multimodal detection and outcomes..  74:53-64. 2013
• Intrinsic connectivity network disruption in progressive supranuclear palsy..  73:603-16. 2013
• Recent trends in cost-related medication nonadherence among stroke survivors in the United States..  73:180-8. 2013
• Ischemic stroke is associated with the ABO locus: the EuroCLOT study..  73:16-31. 2013
• 5-Lipoxygenase gene transfer worsens memory, amyloid, and tau brain pathologies in a mouse model of Alzheimer disease..  72:442-54. 2012
• Inflammatory prostaglandin E2 signaling in a mouse model of Alzheimer disease..  72:788-98. 2012
• Real time estimation of brain water content in comatose patients..  72:344-50. 2012
• Dietary fat types and 4-year cognitive change in community-dwelling older women..  72:124-34. 2012
• Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2..  71:370-84. 2012
• Adenosine A2A receptor gene disruption protects in an α-synuclein model of Parkinson's disease..  71:278-82. 2012
• Amyloid-β oligomerization in Alzheimer dementia versus high-pathology controls..  73:104-19. 2012
• Clinicopathological correlations in corticobasal degeneration..  70:327-40. 2011
• Incidence of dementia and cognitive impairment, not dementia in the United States..  70:418-26. 2011
• Amyloid-β associated cortical thinning in clinically normal elderly..  69:1032-42. 2011
• Familial prion disease with Alzheimer disease-like tau pathology and clinical phenotype..  69:712-20. 2011
• Mediterranean diet and magnetic resonance imaging-assessed cerebrovascular disease..  69:257-68. 2011
• Alternative processing of γ-secretase substrates in common forms of mild cognitive impairment and Alzheimer's disease: evidence for γ-secretase dysfunction..  69:1026-31. 2011
• Angiogenin variants in Parkinson disease and amyotrophic lateral sclerosis..  70:964-73. 2011
• Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease..  70:274-85. 2011
• Variably protease-sensitive prionopathy: a new sporadic disease of the prion protein..  68:162-72. 2010
• Arginine test is not reliable for diagnosing cerebellar multiple system atrophy..  67:404-8. 2010
• Cognition, reserve, and amyloid deposition in normal aging..  67:353-64. 2010
• APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging..  67:122-31. 2010
• Exercise and Alzheimer's disease biomarkers in cognitively normal older adults..  68:311-8. 2010
• Intracortical electroencephalography in acute brain injury..  66:366-77. 2009
• AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location..  65:424-34. 2009
• A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system..  66:48-54. 2009
• Clinical-neuroimaging characteristics of dysexecutive mild cognitive impairment..  65:414-23. 2009
• Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly..  65:176-83. 2009
• Genetic determinants of hair color and Parkinson's disease risk..  65:76-82. 2009
• What causes cell death in Parkinson's disease?.  64 Suppl 2:S3-15. 2008
• The prostaglandin E2 EP2 receptor accelerates disease progression and inflammation in a model of amyotrophic lateral sclerosis..  64:304-14. 2008
• A novel human disease with abnormal prion protein sensitive to protease..  63:697-708. 2008
• Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia..  63:709-19. 2008
• Cystatin C as a marker of cognitive function in elders: findings from the health ABC study..  63:798-802. 2008
• Frequency and course of mild cognitive impairment in a multiethnic community..  63:494-506. 2008
• Extreme cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer's disease presenilin 1 mutation..  61:446-53. 2007
• Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma..  61:25-36. 2007
• Localization of LRRK2 to membranous and vesicular structures in mammalian brain..  60:557-569. 2006
• Trial of celecoxib in amyotrophic lateral sclerosis..  60:22-31. 2006
• Mediterranean diet and risk for Alzheimer's disease..  59:912-21. 2006
• Expectations and challenges in the therapeutic use of neurotrophic factors..  59:444-7. 2006
• Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans..  59:512-9. 2006
• Pesticide exposure and risk for Parkinson's disease..  60:197-203. 2006
• Prion protein codon 129 genotype prevalence is altered in primary progressive aphasia..  58:858-64. 2005
• Sex differences in cell death..  58:317-21. 2005
• A 10-item smell identification scale related to risk for Alzheimer's disease..  58:155-60. 2005
• Pre-existing hypertension and the impact of stroke on cognitive function..  58:68-74. 2005
• Acetylcholinesterase inhibitors reduce brain and blood interleukin-1beta production..  57:741-5. 2005
• Neuroprotection by the PGE2 EP2 receptor in permanent focal cerebral ischemia..  57:758-61. 2005
• Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease..  58:963-7. 2005
• PGE2 receptors rescue motor neurons in a model of amyotrophic lateral sclerosis..  56:240-8. 2004
• Medial temporal lobe function and structure in mild cognitive impairment..  56:27-35. 2004
• Onset of dementia is associated with age at menopause in women with Down's syndrome..  54:433-8. 2003
• Genetics of Parkinson's disease: what do mutations in DJ-1 tell us?.  54:281-2. 2003
• Neuronal overexpression of cyclooxygenase-2 increases cerebral infarction..  54:155-62. 2003
• Alcohol consumption and the incidence of Parkinson's disease..  54:170-5. 2003
• Cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia..  54:115-9. 2003
• Matrix metalloproteinase-9 and spontaneous hemorrhage in an animal model of cerebral amyloid angiopathy..  54:379-82. 2003
• Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease..  52:175-9. 2002
• Combined effect of age and severity on the risk of dementia in Parkinson's disease..  51:722-9. 2002
• Imaging hippocampal function across the human life span: is memory decline normal or not?.  51:290-5. 2002
• Apolipoprotein E affects the central nervous system response to injury and the development of cerebral edema..  51:113-7. 2002
• Minocycline markedly protects the neonatal brain against hypoxic-ischemic injury..  52:54-61. 2002
• Neuroimmunophilins: novel neuroprotective and neuroregenerative targets..  50:6-16. 2001
• Variant Alzheimer's disease with spastic paraparesis and cotton wool plaques is caused by PS-1 mutations that lead to exceptionally high amyloid-beta concentrations..  48:806-8. 2000
• Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease..  46:412-6. 1999
• Differential regional dysfunction of the hippocampal formation among elderly with memory decline and Alzheimer's disease..  45:466-72. 1999
• The absence of an apolipoprotein epsilon4 allele is associated with a more aggressive form of Alzheimer's disease..  41:615-20. 1997
• Pathological correlates of extrapyramidal signs in Alzheimer's disease..  41:368-74. 1997
• Immunosuppressants, immunophilins, and the nervous system..  40:559-60. 1996
• Apolipoprotein E and Alzheimer's disease: ethnic variation in genotypic risks..  37:254-9. 1995
• Increased risk of mortality in Alzheimer's disease patients with more advanced educational and occupational attainment..  37:590-5. 1995
• Neuroprotective effects of gangliosides may involve inhibition of nitric oxide synthase..  37:115-8. 1995
• Amyloid beta protein levels in cerebrospinal fluid are elevated in early-onset Alzheimer's disease..  36:903-11. 1994
• Trinucleotide repeat expansion in neurological disease..  36:814-22. 1994
• Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains..  36:778-86. 1994
• Reactive nitrogen intermediates: effector molecules of immune-mediated inflammatory nervous system disorders?.  33:-. 1993
• Relative sparing of nitric oxide synthase-containing neurons in the hippocampal formation in Alzheimer's disease..  32:818-20. 1992
• A novel neuronal messenger molecule in brain: the free radical, nitric oxide..  32:297-311. 1992
• Thrombotic microangiopathy isolated to the central nervous system..  30:843-6. 1991
• Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer's Disease 2020

Identity

International Standard Serial Number (ISSN)

• 0364-5134
• 1531-8249